Cell-derived microparticles are promising biomarkers for cardiovascular disease risk prediction, but clinical implementation requires sensitive standardized techniques and large prospective studies.
Cell-derived microparticles show promise as biomarkers for cardiovascular risk prediction and treatment monitoring, but methodological standardization is required before clinical implementation.
Cardiovascular diseases (CVDs) are a common cause of death, and a search for biomarkers for risk stratification is warranted. Elevated levels of cell-derived microparticles (MPs) are found in patients with CVD and in groups with risk factors for CVD. Subpopulations of MPs are promising biomarkers for improving risk prediction, as well as monitoring treatment. However, the field has been hampered by technical difficulties, and the ongoing development of sensitive standardized techniques is crucial for implementing MP analyses in the clinic. Large prospective studies are required to establish which MPs are of prognostic value in different patient groups. In this review, we discuss methodological challenges and progress in the field, as well as MP populations that are of interest for further clinical evaluation.
Thulin et al. (Thu,) conducted a review in Cardiovascular Disease. Cell-derived microparticles (MPs) was evaluated. Cell-derived microparticles are promising biomarkers for cardiovascular disease risk prediction, but clinical implementation requires sensitive standardized techniques and large prospective studies.